Ann Oncol:癌症诊断后首发精神障碍与癌症特异性死亡风险相关(全国性队列研究)

2017-06-21 MedSci MedSci原创

癌症的诊断与精神障碍的危险性密切相关,即使在没有精神病史的病人中也存在这种相关性。越来越多的数据表明,精神障碍可能加速肿瘤进展。因此,研究人员假设癌症诊断后的精神障碍可能会增加癌症特异性死亡率的风险进行了该研究。这是来自瑞典的一项全国性的队列研究,包括2004-2009年确诊的244261例癌症患者(随访至2010年)。通过瑞典病人登记,研究人员得到的了癌症患者中所有被临床诊断为心理障碍、情绪障碍

癌症的诊断与精神障碍的危险性密切相关,即使在没有精神病史的病人中也存在这种相关性。越来越多的数据表明,精神障碍可能加速肿瘤进展。因此,研究人员假设癌症诊断后的精神障碍可能会增加癌症特异性死亡率的风险进行了该研究。

这是来自瑞典的一项全国性的队列研究,包括2004-2009年确诊的244261例癌症患者(随访至2010年)。通过瑞典病人登记,研究人员得到的了癌症患者中所有被临床诊断为心理障碍、情绪障碍、焦虑和药物滥用 (ICD10: F10-F16, F18-F19, F32-F33, F40-F41, and F43-45) 者。研究人员进一步将这些精神障碍分为首次发作或反复发作。调整诊断的年龄、性别、时间、教育水平、肿瘤分期、肿瘤类型后,应用Cox回归估计多变量的风险比(HR)和95%可信区间(CI),进而探讨肿瘤诊断和肿瘤特异性死亡与精神障碍的关联。

癌症诊断后,11457名患者被诊断为情绪障碍、焦虑和药物滥用,其中7236名为首发精神障碍患者。首发精神障碍患者的癌症特异性死亡率的风险增加(HR:1.82,95% CI:1.71-1.92),与之相比,复发性精神障碍患者的风险升高较少(HR:1.14,95% CI:1.05-1.24)。首发精神障碍引起的癌症特异性死亡率增加在几乎所有癌症的类型中被观察到,且在局部肿瘤(HR:2,95% CI:1.73-2.31)中的相关性比晚期癌症(HR:1.49,95% CI:1.32-1.69)中更强。

本研究结果表明,癌症患者在确诊后出现首次发作的情绪障碍、焦虑或药物滥用可能会增加其癌症特异性死亡的风险。

原始出处:

Zhu J, Fang F,et al.First-onset Mental Disorders after Cancer Diagnosis and Cancer-specific Mortality: a Nationwide Cohort Study.Ann Oncol. 2017 May 19. doi: 10.1093/annonc/mdx265. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899132, encodeId=6b6d189913249, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Sep 09 06:27:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864967, encodeId=85ec186496e74, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 10 01:27:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255647, encodeId=4a3e125564e43, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545017, encodeId=145a154501ed2, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213832, encodeId=518621383207, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 22 09:10:42 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213528, encodeId=5aec2135283f, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Jun 21 15:32:12 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899132, encodeId=6b6d189913249, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Sep 09 06:27:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864967, encodeId=85ec186496e74, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 10 01:27:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255647, encodeId=4a3e125564e43, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545017, encodeId=145a154501ed2, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213832, encodeId=518621383207, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 22 09:10:42 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213528, encodeId=5aec2135283f, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Jun 21 15:32:12 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
    2017-11-10 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899132, encodeId=6b6d189913249, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Sep 09 06:27:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864967, encodeId=85ec186496e74, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 10 01:27:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255647, encodeId=4a3e125564e43, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545017, encodeId=145a154501ed2, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213832, encodeId=518621383207, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 22 09:10:42 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213528, encodeId=5aec2135283f, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Jun 21 15:32:12 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899132, encodeId=6b6d189913249, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Sep 09 06:27:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864967, encodeId=85ec186496e74, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 10 01:27:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255647, encodeId=4a3e125564e43, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545017, encodeId=145a154501ed2, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213832, encodeId=518621383207, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 22 09:10:42 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213528, encodeId=5aec2135283f, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Jun 21 15:32:12 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1899132, encodeId=6b6d189913249, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Sep 09 06:27:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864967, encodeId=85ec186496e74, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 10 01:27:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255647, encodeId=4a3e125564e43, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545017, encodeId=145a154501ed2, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213832, encodeId=518621383207, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 22 09:10:42 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213528, encodeId=5aec2135283f, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Jun 21 15:32:12 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
    2017-06-22 ylzr123

    认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1899132, encodeId=6b6d189913249, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Sep 09 06:27:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864967, encodeId=85ec186496e74, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 10 01:27:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255647, encodeId=4a3e125564e43, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545017, encodeId=145a154501ed2, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Fri Jun 23 06:27:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213832, encodeId=518621383207, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jun 22 09:10:42 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213528, encodeId=5aec2135283f, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Jun 21 15:32:12 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
    2017-06-21 orangesking

    看看

    0

相关资讯

PNAS:科学家绘制出吸烟导致DNA受损的图谱 引起癌症出现

美国北卡罗来纳大学医学院的研究人员开发出一种高解析度的方法绘制出了吸烟导致的DNA受损。这项技术将帮助我们更好地理解吸烟带来的风险,以及它是如何导致癌症的出现,以及为什么烟民更容易患癌症,甚至是这些癌症如何被预防。这项研究已发表在近日的《PNAS》上。

Am J Hematol:癌症住院患者静脉血栓栓塞风险 KS预测工具是否有效

静脉血栓栓塞(VTE)是一种需要住院患者重点预防的疾病;癌症的风险多样,而预防是一致的。既往证实的工具(Khorana评分,[KS])由5个容易获得的变量组成,可以确定门诊癌症患者的VTE风险,但该工具尚未在住院患者中研究过。2017年6月,发表在《Am J Hematol》的一项回顾性队列研究评价了KS预测癌症住院患者VTE风险的有效性。

Sci Rep:免疫疗法溶瘤病毒与PD-1药物结合,抗癌效果倍增

横纹肌肉瘤是一种骨骼肌细胞癌症,是常见儿童软组织肿瘤。传统的手术治疗通常是可以治愈的,但是需要加入化疗和放疗结合治疗,其中充满了严重的副作用,尤其是对儿童,尤为如此。

CA-Cancer J Clin :微生物在癌症发展和治疗中的作用。

人体拥有大量的微生物群,影响癌症的易感性,其影响的部分原因是:其代谢能力巨大,对免疫细胞的功能产生重要影响。微生物病原体在15%〜20%的癌症病例中驱动肿瘤发生。通过使用宏基因组测序的微生物组研究,研究者们认为存在更多数量的恶性肿瘤与共生微生物群(dysbiosis)的组合变化相关。

Pre Oncology:科学家找到成功“饿死”癌细胞的天然化合物

德克萨斯大学奥斯汀分校的研究人员发现了一种有潜力的天然化合物,这种化合物可以成功“饿死”前列腺癌癌细胞,使肿瘤缩小。这种化合物存在于姜黄,红葡萄皮和苹果皮中,如果将这三者组合,效果似乎更加强大。完整的研究报告发表于《精密肿瘤学》杂志上。

Dev Cell:科学家找到彻底消灭癌细胞的“新武器”

最新研究详细阐述了,死亡细胞如何被取代,如何利用微生物杀死癌细胞,基于这一发现,研究人员找到减少癌变肿瘤的新方法。